Objective To investigate the effectiveness of different calcium concentrations in dialysate for simplified citric acid anticoagulant hemodialysis. Methods A total of 32 hemodialysis patients with high risk of bleeding were treated with 1.25mmol/L (group A) or 1.5 mmol/L (group B) calcium-containing dialysate for 64 times of simplified citric acid anticoagulant hemodialysis by self-crossover control method. Blood free calcium level was measured at different dialysis time points, the pumping speed of citric acid was adjusted, and the dialysis indexes and dialysis adequacy (Kt/V) were recorded. Results ①The anticoagulant efficacies of group A and group B were 100% and 93.8% respectively. ②The pumping speed of citric acid in group A was lower than that in group B [(390.9±24.0) ml/h vs.（410.9±20.7）ml/h, t=-3.569, P=0.001]. In group A, the free calcium after the filter at 2 hours of dialysis [(0.66±0.13) mmol/L vs. (0.80±0.12) mmol/L, t=-4.428, P<0.001) and the free calcium before the filter at 4 hours of dialysis [(0.91±0.11) mmol/L vs. (1.00±0.13) mmol/L, t=-2.917, P=0.005) were lower than those in group B. ③There was no significant difference in Kt/V between the two groups [(1.16±0.22) mmol/L vs. (1.18±0.20)mmol/L, t=-0.380, P=0.706]. Conclusion Dialysate containing calcium 1.5mmol/L can achieve effective anticoagulation with safer blood free calcium concentration, and it may be appropriate for simplified citric acid anticoagulant hemodialysis.
WANG Wei
,
LI Yue-Hong
,
WU Xiang-Lan
,
YANG Hua
,
YANG Hua Jia-Xuan
,
XU Hui-Ying
. Prospective and self-crossover control study of dialysates containing different calcium concentrations for simplified citric acid anticoagulant hemodialysis[J]. Chinese Journal of Blood Purification, 2023
, 22(09)
: 672
-674
.
DOI: 10.3969/j.issn.1671-4091.2023.09.008
[1] Villa G, Ricci Z, Ronco C. Renal Replacement Therapy[J]. Crit Care Clin,2015;31:839-848.
[2] 朱文芳, 何建强, 巢军. 枸橼酸、无肝素和低分子肝素抗凝在血液透析中的应用评价[J]. 临床医学.2015(5):3.
[3] Wei Wang, Shaoyan Zhang, Yuehong Li, et al. Application of simplified regional citrate anticoagulation in hemodialysis patients with high risk of bleeding. Clin Nephrol.2022 Jun,97(6):311-320.
[4] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Europace.2016,18:1609-1678.
[5] Sagedal S, Hartmann A, Osnes K, et al. Intermittent saline flushes during haemodialysis do not alleviate coagulation and clot formation in stable patients receiving reduced doses of dalteparin[J]. Nephrol Dial Transplant.2006,21:444-449.
[6] Dirkes S, Wonnacott R. Continuous Renal Replacement Therapy and Anticoagulation: What Are the Options?[J]. Crit Care Nurse.2016,36:34-41.
[7] Cheng YL, Tang HL, Tong MKL. Clinical practice guidelines for the provision of renal service in Hong Kong: Haemodialysis[J]. Nephrology (Carlton).2019,24 Suppl 1:41-59.
[8] Monchi M. Citrate pathophysiology and metabolism[J]. Transfus Apher Sci,2017;56:28-30.
[9] Buturovic-Ponikvar J.Is regional citrate anticoagulation the future of hemodialysis [J].Ther Apher Dial.2016,20:234-239.
[10] 水光兴,邹峰,贺丹等.简化枸橼酸抗凝在血液透析高危出血倾向患者中的临床应用研究[J].中国中西医结合肾病杂志.2021,22(3):237-239.
[11] 柯小苏,李玉微,骆丽霞.高剂量分段枸橼酸对高通量血液透析抗凝效果临床观察[J].临床肾脏病杂志. 2021,21(8): 677-680.
[12] 席春生,刘飞,刘同存等.高出血风险患者两段法枸橼酸抗凝血液透析的临床观察[J].临床肾脏病杂志.2018,18(3):141-144.
[13] 张少岩,李月红,杨画等.简化枸橼酸抗凝血液透析治疗方案在高出血风险患者血液透析中的应用.临床内科杂志.2021,38(1):34-36.
[14] 邱德俊,李新伦,高卓等.简化法局部枸橼酸与阿加曲班抗凝在高危出血风险血液透析患者中的对比观察[J].临床肾脏病杂志.2020,2(6):449-453.
[15] Borg R,Ugboma D,Walker DM,et al.Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients:A service evaluation following a change in practice[J].J Intensive Care Soc.2017;18:184-192.
[16] Hartmann J, Strobl K, Fichtinger U,et al.In vitro investigations of citrate clearance with different dialysis filters[J].Int J Artif Organs.2012,35:352-359.
